Skip to content
thispeptide

Novi

Novi offers online prescribing for compounded semaglutide and tirzepatide injections. Its product disclosures are more informative than the headline, but contradictory commitment terms need resolving before enrollment.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

The named treatments and compounded-drug limitations are useful disclosures. Clinical identity, monitoring and a conflict between month-to-month advertising and the subscription contract remain important questions before starting.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Novi is a technology platform arranging independent clinical review and pharmacy fulfillment. Its homepage lists weekly semaglutide and tirzepatide injections and explicitly says the program includes compounded preparations. It also lists several branded products, without a complete branded purchase quote. The intake is described as a short online evaluation followed by a provider’s decision. Completing that screen does not establish a treatment relationship or guarantee prescribing. A service that looks simple at the point of enrollment still needs a clear plan for monitoring, side effects and decisions about continuing treatment.

What Novi prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)Price not published
  • TirzepatideFDA-approved
    • Injection (compounded)Price not published

The named compounded injections are intended for clinician-directed weight management. Novi’s own disclaimer says they are not approved generics and have not been shown to reproduce the results of an approved product. That limitation deserves equal attention to the prominent weight-loss promises. A patient should understand why the preparation is proposed, which alternatives were considered and what outcome will be monitored. A calculator based on current body weight is not an individualized prognosis.

Who prescribes

A licensed clinician

The public offer does not name the individual treating prescriber. The homepage says medical care is provided by independent U.S.-licensed clinicians. It does not identify the practice or individual assigned to each applicant before enrollment. Its corporate names also vary between the homepage, terms and consent: Novi Health International, Novi International and Novi Health appear in those documents. These administrative names are not a substitute for the treating practice’s identity. Request the prescriber’s name and professional entity on the actual consent and prescription. The site says the dispensing pharmacy is identified in order confirmation messages, so that assignment should also be checked before treatment begins.

The advertised sequence is a short evaluation, clinical review and delivery when a prescription is appropriate. Ongoing support and one-to-one medical access are promoted, with clinical questions directed through the patient portal. The pages do not establish a universal live-visit schedule or a specific response window for every prescriber. Ask what happens when written messages cannot adequately address a new symptom. Shipping estimates begin after approval and preparation; they do not establish the depth of the consultation. Keep the clinical follow-up arrangement separate from a promise of quick delivery.

Are labs required?

Not mentioned

The public offer does not establish a universal laboratory panel or inclusive testing charge. The intake may gather medical history, but that does not show that every applicant can safely begin without recent results. Ask which tests are needed, who interprets them and whether a local clinician must arrange additional examination. Product potency checks are not the same as patient monitoring. The follow-up plan should explain how clinical progress is assessed and what happens if the clinician decides that remote care is no longer sufficient.

Ready to start with Novi?

Prices and plans are set on the seller's own site.

What it claims, and what it cites

The page leads with substantial weight-loss promises and a short delivery sequence. Its detailed disclaimer is more cautious: results vary, compounded products are not FDA-approved and no equivalent clinical result is established. Those qualifications should govern the conversation with the prescriber. The pharmacy is described in general terms before order confirmation. Technical or certification language does not identify the dispenser responsible for the actual preparation. Verify that pharmacy and the prescription rather than relying on a package illustration or a broad claim about a U.S. facility.

How it bills

The footer distinguishes $129 monthly semaglutide and $169 monthly tirzepatide from lower quarterly equivalents. However, the linked terms describe a three-month commitment charged at purchase, with a fifteen-day cancellation cutoff after that commitment. They also default to renewal every thirty days. These statements do not establish one consistent freely cancelable monthly offer. Obtain the agreement governing the actual selection before paying. Consultation and shipping are advertised as included. The separate returns policy declines product returns, while the terms allow an initial refund when prescribing is medically inappropriate.

For and against

  • For: Named ingredients and weekly injection routes
  • For: Compounded limitations stated in detail
  • For: Consultation and delivery inclusion described
  • For: Clinical questions directed to a patient portal
  • Against: Monthly advertising conflicts with three-month contract language
  • Against: Treating practice not identified in advance
  • Against: Universal laboratory plan is not established
  • Against: Returns are restricted after purchase

The evidence behind what it sells

Right for

Someone willing to resolve the contract conflict and verify the assigned prescriber and pharmacy before considering a compounded weight-management plan.

Look elsewhere if

A patient seeking an uncomplicated cancelable trial month or interpreting a weight-loss calculator as a likely personal result.

Other sellers for weight

Novi

Frequently asked questions

Is the lowest advertised amount a one-month purchase?
No. The footer ties $99 semaglutide and $139 tirzepatide equivalents to three-month payments. Separately advertised monthly options conflict with the linked commitment terms.
Is the pharmacy identified publicly for every prescription?
The disclaimer says the pharmacy is identified in order confirmation. Confirm that assignment and the actual prescription before using the medication.
Does approval happen automatically after the questionnaire?
No. Novi says an independent clinician decides whether treatment is appropriate, and completing the screen does not guarantee a prescription.
What must be clarified before paying?
Ask which contract controls the selected plan, how much is charged at purchase, the renewal interval and the last date to stop another charge.

Sources

  • Named treatments, billing disclosures and clinical limitations
  • Commitment and cancellation requirements
  • Product return policy
  • Medical consent and administrative authorization
  • Health-information responsibilities

See what Novi prescribes today

Novi sets its own prices, plans and the states it serves. Check them before you start.

Written by Leah Garner from Novi’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.